electroCore Expands Intellectual Property Portfolio
electroCore (Nasdaq: ECOR) has strengthened its intellectual property portfolio with two new U.S. patents granted by the USPTO. The first patent (No. 12,208,263), issued on January 28, 2025, covers methods for vagal nerve stimulation using electrodes with conductive gel on the neck, including position adjustment based on pressure sensation.
The second patent (No. 12,213,795), issued on February 4, 2025, relates to systems and methods for nerve modulation that incorporate data storage of electrical impulse parameters and patient monitoring, including the ability to track user status data such as headache severity.
electroCore (Nasdaq: ECOR) ha rafforzato il suo portafoglio di proprietà intellettuale con due nuovi brevetti statunitensi concessi dal USPTO. Il primo brevetto (No. 12,208,263), rilasciato il 28 gennaio 2025, riguarda metodi per la stimolazione del nervo vago utilizzando elettrodi con gel conduttivo sul collo, inclusa la regolazione della posizione in base alla sensazione di pressione.
Il secondo brevetto (No. 12,213,795), rilasciato il 4 febbraio 2025, riguarda sistemi e metodi per la modulazione dei nervi che incorporano l'archiviazione dei dati relativi ai parametri degli impulsi elettrici e al monitoraggio del paziente, inclusa la capacità di tracciare dati sullo stato dell'utente come la gravità del mal di testa.
electroCore (Nasdaq: ECOR) ha fortalecido su cartera de propiedad intelectual con dos nuevas patentes de EE. UU. concedidas por la USPTO. La primera patente (No. 12,208,263), emitida el 28 de enero de 2025, cubre métodos para la estimulación del nervio vago utilizando electrodos con gel conductor en el cuello, incluida la ajuste de posición basado en la sensación de presión.
La segunda patente (No. 12,213,795), emitida el 4 de febrero de 2025, se refiere a sistemas y métodos para la modulación de nervios que incorporan el almacenamiento de datos de parámetros de impulsos eléctricos y monitoreo de pacientes, incluida la capacidad de rastrear datos del estado del usuario, como la gravedad de la cefalea.
electroCore (Nasdaq: ECOR)는 USPTO에서 부여한 두 개의 새로운 미국 특허로 지적 재산 포트폴리오를 강화했습니다. 첫 번째 특허(No. 12,208,263)는 2025년 1월 28일에 발급되었으며, 목에서 전도성 젤이 있는 전극을 사용한 미주 신경 자극 방법을 포함하며, 압력 감각에 따라 위치 조정이 가능합니다.
두 번째 특허(No. 12,213,795)는 2025년 2월 4일에 발급되었으며, 전기 자극 매개변수의 데이터 저장 및 환자 모니터링을 포함하는 신경 조절을 위한 시스템 및 방법을 다룹니다. 여기에는 두통의 심각도와 같은 사용자 상태 데이터를 추적할 수 있는 기능이 포함됩니다.
electroCore (Nasdaq: ECOR) a renforcé son portefeuille de propriété intellectuelle avec deux nouveaux brevets américains accordés par l'USPTO. Le premier brevet (n° 12,208,263), délivré le 28 janvier 2025, concerne des méthodes de stimulation du nerf vague utilisant des électrodes avec un gel conducteur sur le cou, y compris l'ajustement de la position en fonction de la sensation de pression.
Le deuxième brevet (n° 12,213,795), délivré le 4 février 2025, concerne des systèmes et méthodes de modulation nerveuse qui intègrent le stockage de données des paramètres d'impulsions électriques et la surveillance des patients, y compris la capacité de suivre des données sur l'état de l'utilisateur, telles que la gravité des maux de tête.
electroCore (Nasdaq: ECOR) hat sein Portfolio an geistigem Eigentum mit zwei neuen US-Patenten, die vom USPTO gewährt wurden, gestärkt. Das erste Patent (Nr. 12,208,263), das am 28. Januar 2025 erteilt wurde, betrifft Methoden zur Vagusnervstimulation mit Elektroden, die mit leitfähigem Gel am Hals versehen sind, einschließlich der Positionsanpassung basierend auf Druckempfindungen.
Das zweite Patent (Nr. 12,213,795), das am 4. Februar 2025 erteilt wurde, betrifft Systeme und Methoden zur Nervenmodulation, die die Datenspeicherung von elektrischen Impulsparametern und die Patientenüberwachung beinhalten, einschließlich der Fähigkeit, Nutzerdaten wie die Schwere von Kopfschmerzen zu verfolgen.
- Expansion of patent portfolio strengthening intellectual property protection
- New patents cover both treatment methods and monitoring systems, broadening technology scope
- None.
Insights
The USPTO's grant of two strategic patents significantly bolsters electroCore's competitive position in the rapidly growing $7.8 billion neurostimulation market. The first patent strengthens their proprietary approach to non-invasive vagus nerve stimulation (nVNS) by protecting their electrode-gel interface methodology, which is important for treatment efficacy and user comfort. This technical advantage creates meaningful barriers to entry for competitors attempting to develop similar non-invasive solutions.
The second patent's focus on remote therapy and monitoring capabilities is particularly valuable in today's healthcare landscape, where remote patient monitoring reimbursement has expanded substantially. This intellectual property protection could enable electroCore to develop new revenue streams through digital health initiatives and data monetization. The ability to collect and analyze user status data, especially regarding headache severity, positions the company to build valuable real-world evidence databases that could support expanded insurance coverage and market adoption.
These patents extend protection for electroCore's core technology until at least 2042, providing long-term market exclusivity. The company's growing IP portfolio, now encompassing precise stimulation methods and digital health capabilities, enhances its attractiveness as a potential acquisition target for larger medical device companies seeking to enter the neuromodulation space. While patent issuance alone doesn't guarantee commercial success, these additions to electroCore's IP estate materially strengthen their competitive moat and future monetization opportunities.
electroCore Granted Two New U.S. Patents
ROCKAWAY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received two patent issue notifications from the United States Patent and Trademark Office (USPTO).
US Patent No. 12,208,263 entitled “Devices and Methods for Vagal Nerve Stimulation” was issued on January 28, 2025 and generally relates to methods for modulating the vagus nerve by positioning an electrode in contact with an electrically conductive gel on the neck of the user, delivering an electrical impulse to the vagus nerve and adjusting a position of the electrode on the neck based on a pressure sensation of the electrode against the neck.
US Patent No. 12,213,795 entitled “Devices and Methods for Remote Therapy and Patient Monitoring” was issued on February 4, 2025 and generally relates to systems and methods for modulating a nerve within a user that include storing data related to parameters of an electrical impulse applied to the nerve, collecting user status data from the patient and comparing the user status data with the parameters of the electrical impulse. The user status data may include, for example, the severity of a headache.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What are the two new patents granted to electroCore (ECOR) in early 2025?
What technology does electroCore's (ECOR) new vagal nerve stimulation patent cover?
How does electroCore's (ECOR) new patient monitoring patent work?
What is the significance of electroCore's (ECOR) new patents for their bioelectronic medicine business?
